Medical condition
Metastatic Breast Cancer
Metastatic Breast Cancer is a medical condition tracked by NovaPharmaNews across 12 associated drugs and ongoing industry coverage. Explore approved and pipeline therapies, regulatory status, and the latest developments.
Associated drugs & therapies
- docetaxel (DOCETAXEL ACCORD) Antineoplastic and immunomodulating agents (L01)
- capecitabine (CAPECITABINE SANDOZ) Antineoplastic and immunomodulating agents (L01)
- doxorubicin hydrochloride (CELDOXOME PEGYLATED LIPOSOMAL) Antineoplastic and immunomodulating agents (L01)
- paclitaxel (PACLITAXEL ACCORD) Antineoplastic and immunomodulating agents (L01)
- bevacizumab (ABEVMY) Antineoplastic and immunomodulating agents (L01)
- fulvestrant (FULVESTRANT ACCORD) Antineoplastic and immunomodulating agents (L02)
- abemaciclib (VERZENIO) Antineoplastic and immunomodulating agents (L01)
- pertuzumab (PERJETA) Antineoplastic and immunomodulating agents (L01)
- capivasertib (TRUQAP) Antineoplastic and immunomodulating agents (L01)
- olaparib (LYNPARZA) Antineoplastic and immunomodulating agents (L01)
- palbociclib (IBRANCE) Antineoplastic and immunomodulating agents (L01)
- ribociclib (KISQALI) Antineoplastic and immunomodulating agents (L01)
Latest Metastatic Breast Cancer news
FDA Approves Generic Eribulin Mesylate for Metastatic Breast Cancer
The U.S. Food and Drug Administration (FDA) has approved an abbreviated new drug application (ANDA) for generic eribulin mesylate injection. This approval offers a new therapeutic option for patients with pretreated metastatic breast cancer and unresectable or metastatic liposarcoma.
FDA Approval NanoPharm Therapy: Accelerated OK for Metastatic Breast Cancer
The FDA has granted accelerated approval for NanoPharm Therapy, a groundbreaking treatment for metastatic breast cancer, paving the way for innovative patient care.